Product Description
Cancer Molecular Diagnostics: Markets, Strategies and Trends, Volume & Price Forecasts by Cancer Type, Companion Dx and Country with Executive and Consultant Guides and COVID-19 Recession Forecast Revisions 2022 to 2026
“Companion Diagnostics and Liquid Biopsy drive market growth while lowering costs. COVID causes resources shift.....”
A market with fundamental growth factors is impacted by the COVID-19 pandemic. The cancer molecular diagnostics market is positioned to directly benefit from the explosion in genomics knowledge, however shifting resources to deal with the COVID emergency may interrupt growth.
A range of dynamic trends are pushing market growth and company valuations, such as:
- Personalized medicine
- Pharmacogenomics
- Liquid biopsy
- Emergence of new economies with large markets
- Greater understanding of the role of genetic material in disease and health
Working against this dynamic market are the forces of the COVID-driven recession. Our latest numbers factor in the different COVID forces, their timing, and their effect on market growth.
Based on extensive research, the testing volume data is broken down into price and volume allowing researchers and investors to quickly create informed and reasonable forecasts of demand. In addition customization work, breakouts for particular segments, assistance and support is included free of charge with the corporate license.
We include a special segment on Cancer Companion Diagnostics (CDx), a new segment of the market that is reshaping the industry.
The report includes a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
Subscription deliverables:
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
